These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 19474069

  • 1. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
    Almahmoud I, Kay E, Schneider D, Maurin M.
    J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
    [Abstract] [Full Text] [Related]

  • 2. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 3. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
    Beeton ML, Chalker VJ, Kotecha S, Spiller OB.
    J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
    [Abstract] [Full Text] [Related]

  • 4. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK, Nair S, Wain J.
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
    Walkty A, Boyd DA, Gravel D, Hutchinson J, McGeer A, Moore D, Simor A, Suh K, Taylor G, Miller M, Mulvey MR, Canadian Nosocomial Infection Surveillance Program.
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG, Rodríguez-Tarazona RE, García-Rodríguez JA, Muñoz-Bellido JL.
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, Moriya K, Koike K.
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [Abstract] [Full Text] [Related]

  • 11. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).
    Preisler A, Heisig P.
    J Antimicrob Chemother; 2009 Feb; 63(2):290-4. PubMed ID: 19033246
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J.
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [Abstract] [Full Text] [Related]

  • 13. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
    Kim JM, Kim JS, Kim N, Jung HC, Song IS.
    J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
    [Abstract] [Full Text] [Related]

  • 14. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S.
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
    Zhou Y, Yu L, Li J, Zhang L, Tong Y, Kan B.
    Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
    [Abstract] [Full Text] [Related]

  • 19. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
    De Vecchi E, Nicola L, Ossola F, Drago L.
    J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
    [Abstract] [Full Text] [Related]

  • 20. Rapid detection of gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae by denaturing high-performance liquid chromatography.
    Shigemura K, Shirakawa T, Okada H, Tanaka K, Udaka T, Kamidono S, Arakawa S, Gotoh A.
    J Microbiol Methods; 2004 Dec; 59(3):415-21. PubMed ID: 15488283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.